Natriuretic Peptides, Respiratory Disease, and the Right Heart

Yap, L B; Mukerjee, Dev; Timms, Philip; Ashrafian, Houman; Coghlan, J G

doi:10.1378/chest.126.4.1330

Cited by 139 publications

(103 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this context, data on MR-proANP levels in more localized forms of infection are scarce. Slightly increased levels of ANP were recorded in lung diseases like COPD, asthma and acute pulmonary embolism [39]. In a recent study it has been shown that MRproANP levels in children with pneumonia were significantly higher when compared with controls [1].…”

Section: Discussionmentioning

confidence: 99%

“…Thereby, the pathophysiological mechanisms for the increase of proANP are incompletely understood. It is thought that over-secretion of the hormone is caused by hypoxia, leading to pulmonary vasoconstriction, pulmonary hypertension, and right-heart overload [39,40]. Accordingly, exposure of healthy individuals to hypoxia gradually raises circulating ANP levels [41][42][43][44].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating levels of pro‐atrial natriuretic peptide in lower respiratory tract infections

Müller

Süess

Schuetz

et al. 2006

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Circulating levels of pro‐atrial natriuretic peptide in lower respiratory tract infections

Müller

Süess

Schuetz

et al. 2006

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…In the present article, those of most relevance are outlined and their clinical application discussed. hormones that are released from cardiac myocytes in response to cardiac pressure and volume overload [8]. ANP is released from storage granules in atrial tissue, while BNP is secreted from ventricular tissue in a constitutive fashion.…”

Section: Biomarkers In Pulmonary Hypertensionmentioning

confidence: 99%

Biomarkers in pulmonary hypertension

Warwick

Thomas²,

Yates³

2008

European Respiratory Journal

132

View full text Add to dashboard Cite

There have been significant recent advances in the understanding of the pathophysiology of pulmonary hypertension, and a growing number of therapeutic agents have become available to the treating physician. Traditional methods of diagnosing and monitoring this condition have comprised echocardiography and right heart catheterisation, in addition to functional measures, such as estimation of functional class and the 6-min walk test. An increasing number of biomarkers have been described that are elevated in pulmonary hypertension and which may assist the clinician in diagnosis and in the assessment of disease severity and response to treatment.The present article details the more important biomarkers, their potential applications and the evidence supporting their use.

show abstract

“…In patients with right ventricular pressure overload due to primary pulmonary hypertension and thromboembolism, BNP levels are higher than that in those patients with right ventricular volume overload due to atrial septal defect [20][21][22].…”

Section: Discussionmentioning

confidence: 86%